15 different GP practices across Ireland who were deemed suitable by their physician to start treatment with SFC (any dose). HRQOL was assessed using the SF-36 before treatment and 12 weeks later following treatment. RESULTS: Data was evaluable for 90 patients (71%; asthma, 21%; COPD, 8%; bronchitis or cough). Fifty-four percent of patients were female and 33% were over 60 years of age. At baseline, HRQOL scores for all health attributes for all patients was less than that of the general population. The biggest difference was in the role physical and general health attributes (37 and 24 points respectively). After 12 weeks, SFC had a significant positive impact on most health attributes. The biggest improvements were observed in the role physical, vitality, social functioning and role emotional attributes with an average difference of 15.5, 11.5, 11.1 and 10.9 points respectively (all p < 0.004). CONCLUSION: This study showed that respiratory diseases have a negative impact on patient's quality of life. However, treatment with SFC resulted in positive improvements in the quality of life of patients with respiratory diseases like asthma and COPD. OBJECTIVES: Chronic obstructive pulmonary disease (COPD) imposes a tremendous economic and humanistic burden on health care systems worldwide. The EQ-5D is a generic measure of health-related quality of life (HRQL) that can help to better
understand the impact of COPD. The aim of this study was to estimate EQ-5D index-based utility scores associated with different levels of severity of COPD according to Global initiative of Chronic Obstructive Lung Disease (GOLD) stage. METHODS: A structured literature search was conducted in EMBASE and MEDLINE (Jan 1988 to Jan 2007) using keywords relevant to respiratory disease and EQ-5D. Original research studies in COPD that reported EQ-5D summary scores were selected for inclusion. Pooled summary scores for UK-based index were estimated using a fixed-effects estimate for COPD overall and by GOLD stage (Stage I [least severe] to Stage IV [most severe]). RESULTS: Of 15 original research studies identified prior to screening, 8 reported EQ-5D index-based summary scores by severity. Utility scores which ranged from 0.52 (SD 0.16) to 0.84 (SD 0.15). Pooled average utility scores (95% CI) by GOLD stage were as follows: stage I = 0.74 (0.62-0.87); stage II = 0.74 (0.66-0.83); stage III = 0.69 (0.60-0.78); and stage IV = 0.61 (0.44-0.77). CONCLUSION: Synthesis of the current literature provided evidence that HRQL decreases with severity of COPD. Utilities associated with stage of severity may be useful for modeling outcomes and facilitating quality-adjusted life-year calculations in economic evaluations of COPD.
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DEVELOPMENT OF PREFERENCE-BASED EQ-5D UTILITY VALUES FOR THE ST GEORGE'S RESPIRATORY QUESTIONNAIRE-CHRONIC OBSTRUCTIVE PULMONARY DISEASE (SGRQ-COPD)
Vardeva K 1 , Spencer MD 2 , Punekar Y 3 1 GlaxoSmithKline, Greenford, Middlesex, UK, 2 Elan Pharma, Stevenage, Hertfordshire, UK, 3 Schering-Plough Ltd, Welwyn Garden City, Hertfordshire, UK OBJECTIVES: To model the relationship between St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease (SGRQ-COPD) and utilities based on EQ-5D so as to estimate preference-based utilities for COPD patients. METHODS: Dataset comprised of a one-year clinical study of 845 patients. 559 patients completed all items of the SGRQ-COPD and EQ-5D at baseline. Ordinary least squares regression was used to predict EQ-5D utilities based on responses to SGRQ-COPD. Following identification of significant patient characteristics, significant components and individual items measured in SGRQ-COPD were included using stepwise selection regression with an additive specification to obtain the preferred algorithm to explain EQ-5D utilities. Adjusted R-squared and error of prediction (root mean-squared error: RMSE), were used to judge goodness of fit. The preferred algorithm was validated for predictive ability using end of trial data. RESULTS: The preferred algorithm included the following terms (coefficient): constant (+1.0050), symptoms (-0.0006), activity (-0.0019) and impacts (+0.0019) component scores, one activity item-Item 27 'I take a long time to get washed or dressed' (-0.0780), one symptom item-Item 5-'I have had 3 or more attacks of chest trouble in the last year' (-0.0480), and two patient characteristics, smoking history (-0.0160) and gender (+0.0304). Adjusted R-squared was 43.45% and RMSE was 0.1452. In the validation analysis, this algorithm explained 39% of the variation in utilities derived from EQ-5D. The algorithm that excluded items 27 and 5, but included all three components and two patient characteristics, had adjusted R-squared of 41.11% and RMSE of 0.1482. Alternative specifications applying a logistic transformation and Tobit regression did not improve on this model. CONCLUSION: The regression model enables utilities to be estimated for study patients with SGRQ-COPD measurements but for whom no preference-based instrument has been administered. The approach appears fairly robust based on the explanatory power of the algorithm and validation results.
PRS17
SELECTION OF UTILITY INSTRUMENTS FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Lloyd A, Meguro M United BioSource Corporation, London, UK OBJECTIVES: Agencies such as NICE in the UK have specific requirements for economic evaluations. NICE specify how utility data should be collected and used in such analyses. The present review aimed to: 1) identify which utility measures have been used in asthma and COPD; 2) compare their measurement properties; and 3) determine if they meet NICE requirements. METHODS: A literature (Embase, PubMed) and internet (Google, PROQOLID) search for studies including utility measures in asthma and COPD was completed for the last 10 years. It identified 41 and 24 studies respectively. The evidence regarding each measure was critically appraised and summarised in terms of our three criteria. RESULTS: Asthma and COPD search generated 41 and 24 hits respectively. The following generic instruments had been used in asthma or COPD studies: EQ-5D, 15D, HUI-2, SF-6D [1]. Disease specific utility measures were also identified: ALQ-5D, Asthma Symptoms Utility Index (ASUI) and the SGRQ-U. The ALQ-5D and the SGRQ-U are derived from the Asthma Quality of life Questionnaire and St Georges Respiratory Questionnaire respectively. The EQ-5D has been most commonly used and one comparison study found it to be more sensitive than the SF-6D. Measurement properties and appropriateness for all measures will be summarised. CONCLU-SION: Utility measures have been quite widely used in asthma and COPD. EQ-5D, SF-6D, ALQ-5D and HUI-2 would all in principle be suitable for NICE, but EQ-5D is probably the safest Abstracts A311
